Restoring multidrug resistance-associated protein 3 attenuates cell proliferation in the polycystic kidney

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 9, 2015, Pages F1004-F1011

  Chang, Eun Sun ^a   Park, Eun Young ^a   Woo, Yu Mi ^a   Kang, Duk Hee ^b   Hwang, Young Hwan ^c   Ahn, Curie ^d   Park, Jong Hoon ^a  

^a Sookmyung Women's University   (South Korea)

^b Ewha Womans University   (South Korea)

^c Eulji General Hospital   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

Cell proliferation; Cystogenesis; Multidrug resistance associated protein 3 (MRP3); Polycystic kidney

Indexed keywords

B RAF KINASE; CRE RECOMBINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; BRAF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVE SITE; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRACELLULAR SIGNALING; KIDNEY CORTEX; KIDNEY EPITHELIUM; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY PROXIMAL TUBULE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; CASE CONTROL STUDY; DISEASE MODEL; DOG; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KIDNEY; MDCK CELL LINE; METABOLISM; PATHOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RNA INTERFERENCE; TIME;

ANIMALS; CASE-CONTROL STUDIES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOGS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; KIDNEY; MADIN DARBY CANINE KIDNEY CELLS; MAP KINASE KINASE KINASES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTO-ONCOGENE PROTEINS B-RAF; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84930856063     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00159.2014     Document Type: Article

References (29)

1. Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther300: 97–104, 2002
2. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med9: 1323–1326, 2003
3. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med359: 1477–1485, 2008
4. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol21: 1052–1061, 2010
5. Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int79: 502–511, 2011
6. Jeong HW, Jeon US, Koo BK, Kim WY, Im SK, Shin J, Cho Y, Kim J, Kong YY. Inactivation of Notch signaling in the renal collecting duct causes nephrogenic diabetes insipidus in mice. J Clin Invest119: 3290–3300, 2009
7. Kelsey R. Polycystic kidney disease: tolvaptan in ADPKD-TEMPO 3:4 trial results. Nat Rev Nephrol9: 1, 2013
8. Konig J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology29: 1156–1163, 1999
9. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA96: 6914–6919, 1999
10. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology126: 322–342, 2004
11. Li C, Krishnamurthy PC, Penmatsa H, Marrs KL, Wang XQ, Zaccolo M, Jalink K, Li M, Nelson DJ, Schuetz JD, Naren AP. Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell131: 940–951, 2007
12. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3=,5=-cyclic monophosphate. Gastroenterology132: 1104–1116, 2007
13. Nagao S, Yamaguchi T, Kusaka M, Maser RL, Takahashi H, Cowley BD, Grantham JJ. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int63: 427–437, 2003
14. Novalic Z, van der Wal AM, Leonhard WN, Koehl G, Breuning MH, Geissler EK, de Heer E, Peters DJ. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol23: 842–853, 2012
15. Park EY, Seo MJ, Park JH. Effects of specific genes activating RAGE on polycystic kidney disease. Am J Nephrol32: 169–178, 2010
16. Peces R, Cuesta-Lopez E, Peces C, Perez-Duenas V, Vega-Cabrera C, Selgas R. Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease. Int Urol Nephrol43: 565–569, 2011
17. Rost D, Mahner S, Sugiyama Y, Stremmel W. Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. Am J Physiol Gastrointest Liver Physiol282: G720–G726, 2002
18. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene- Iordache B, Remuzzi G, Epstein FH. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int68: 206–216, 2005
19. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, Elferink RP, van der Valk P, Borst P, Scheper RJ. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest82: 193–201, 2002
20. Smith LA, Bukanov NO, Husson H, Russo RJ, Barry TC, Taylor AL, Beier DR, Ibraghimov-Beskrovnaya O. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol17: 2821–2831, 2006
21. Stork PJ. Does Rap1 deserve a bad Rap? Trends Biochem Sci28: 267–275, 2003
22. Takiar V, Nishio S, Seo-Mayer P, King JD Jr, Li H, Zhang L, Karihaloo A, Hallows KR, Somlo S, Caplan MJ. Activating AMPactivated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA108: 2462–2467, 2011
23. Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wuthrich RP. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol5: 1312–1329, 2010
24. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med367: 2407–2418, 2012
25. Torres VE, Harris PC. Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol2: 40–55, 2006
26. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med10: 363–364, 2004
27. Vlaming ML, van Esch A, Pala Z, Wagenaar E, van de Wetering K, van Tellingen O, Schinkel AH. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther8: 3350–3359, 2009
28. Wallace DP. Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta1812: 1291–1300, 2011
29. Wang Z, Zhou Q, Kruh GD, Gallo JM. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos39: 2155–2161, 2011.